Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Therapeutic advances in relapsed or refractory multiple myeloma.

Anderson KC.

J Natl Compr Canc Netw. 2013 May;11(5 Suppl):676-9. Review.

PMID:
23704241
2.

The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies.

Moreau P.

Semin Hematol. 2012 Jul;49 Suppl 1:S33-46. doi: 10.1053/j.seminhematol.2012.05.004.

PMID:
22727391
3.

Clinical roundtable monograph. Emerging treatment options for relapsed and refractory multiple myeloma.

Siegel DS, Vij R, Jakubowiak AJ.

Clin Adv Hematol Oncol. 2011 Apr;9(4):1-15.

PMID:
21928467
4.

Multiple myeloma, version 1.2013.

Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA Jr, Gasparetto C, Hernandez-Illizaliturri F, Huff CA, Kassim A, Krishnan AY, Liedtke M, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Yunus F, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2013 Jan 1;11(1):11-7.

PMID:
23307977
5.

Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.

Palumbo A, Attal M, Roussel M.

Clin Cancer Res. 2011 Mar 15;17(6):1253-63. doi: 10.1158/1078-0432.CCR-10-1925. Review.

6.

Emerging therapies for multiple myeloma.

Dingli D, Rajkumar SV.

Oncology (Williston Park). 2009 Apr 30;23(5):407-15. Review.

7.

Management of relapsed and relapsed/refractory multiple myeloma.

Laubach JP, Mitsiades CS, Mahindra A, Luskin MR, Rosenblatt J, Ghobrial IM, Schlossman RL, Avigan D, Raje N, Munshi NC, Anderson KC, Richardson PG.

J Natl Compr Canc Netw. 2011 Oct;9(10):1209-16.

PMID:
21975917
8.

Novel drug combinations for the management of relapsed/refractory multiple myeloma.

Usmani SZ, Lonial S.

Clin Lymphoma Myeloma Leuk. 2014 Sep;14 Suppl:S71-7. doi: 10.1016/j.clml.2014.06.016. Review.

PMID:
25486960
9.

Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.

Richardson P.

Semin Hematol. 2005 Oct;42(4 Suppl 4):S9-15. Review.

PMID:
16344100
10.

Carfilzomib.

Kortuem KM, Stewart AK.

Blood. 2013 Feb 7;121(6):893-7. doi: 10.1182/blood-2012-10-459883. Review.

11.

Recent advances in myeloma treatment.

Schots R.

Transfus Apher Sci. 2011 Apr;44(2):223-9. doi: 10.1016/j.transci.2011.01.018.

PMID:
21349768
12.

Treatment of relapsed and refractory myeloma.

Reece DE, Leitch HA, Atkins H, Voralia M, Canning LA, LeBlanc R, Belch AR, White D, Kovacs MJ.

Leuk Lymphoma. 2008 Aug;49(8):1470-85. doi: 10.1080/10428190802064941. Review.

PMID:
18608859
13.

Current strategies for treatment of relapsed/refractory multiple myeloma.

Laubach JP, Voorhees PM, Hassoun H, Jakubowiak A, Lonial S, Richardson PG.

Expert Rev Hematol. 2014 Feb;7(1):97-111. doi: 10.1586/17474086.2014.882764. Review.

PMID:
24471924
14.

Pomalidomide therapy for myeloma.

Schey S, Ramasamy K.

Expert Opin Investig Drugs. 2011 May;20(5):691-700. doi: 10.1517/13543784.2011.567265. Review.

PMID:
21413906
15.

Emerging therapies for the treatment of relapsed or refractory multiple myeloma.

Dimopoulos MA, San-Miguel JF, Anderson KC.

Eur J Haematol. 2011 Jan;86(1):1-15. doi: 10.1111/j.1600-0609.2010.01542.x. Review.

PMID:
20942854
16.

Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives.

Jakubowiak A.

Semin Hematol. 2012 Jul;49 Suppl 1:S16-32. doi: 10.1053/j.seminhematol.2012.05.003. Review.

PMID:
22727389
17.

Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma.

Hus M, Grzasko N, Szostek M, Pluta A, Helbig G, Woszczyk D, Adamczyk-Cioch M, Jawniak D, Legiec W, Morawska M, Kozinska J, WaciƄski P, Dmoszynska A.

Ann Hematol. 2011 Oct;90(10):1161-6. doi: 10.1007/s00277-011-1276-2.

18.

New developments in post-transplant maintenance treatment of multiple myeloma.

Liu H, McCarthy P.

Semin Oncol. 2013 Oct;40(5):602-9. doi: 10.1053/j.seminoncol.2013.07.008. Review.

PMID:
24135405
19.

Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma.

Terpos E, Kanellias N, Christoulas D, Kastritis E, Dimopoulos MA.

Onco Targets Ther. 2013 May 10;6:531-8. doi: 10.2147/OTT.S34498.

20.

Clinical experience with thalidomide and lenalidomide in multiple myeloma.

Moehler T.

Curr Cancer Drug Targets. 2012 May;12(4):372-90. Review.

PMID:
22229246
Items per page

Supplemental Content

Support Center